Core Viewpoint - The supply-side constraints for the third-generation refrigerants are expected to persist until 2026, with potential tightening in the supply of R32, R134a, and R125 [1] Group 1: Demand and Market Trends - The demand for refrigerants is strongly driven by the growth in new energy vehicles, air conditioning, and foreign trade, leading to a sustained increase in industry prosperity [1] - The industry is experiencing a dual boost from both policy and technological advancements, which is expected to drive up the prices of third-generation refrigerants [1] Group 2: Investment Opportunities - There are significant opportunities for companies that focus on industry leaders with advanced patents and synchronized capacity layouts [1] - Companies involved in third-generation refrigerants are likely to benefit significantly from the ongoing market trends and technological shifts [1]

Core Viewpoint - The supply-side constraints for third-generation refrigerants are expected to persist until 2026, with R32, R134a, and R125 supplies likely to tighten further. The demand side is strongly stimulated by the growth in new energy vehicles, air conditioning, and foreign trade, leading to a sustained increase in industry prosperity. The report suggests capitalizing on the dual opportunities of rising prices for third-generation refrigerants and the technological iteration of fourth-generation refrigerants driven by both policy and technology [1] Group 1 - Supply-side limitations for third-generation refrigerants are projected to continue until 2026 [1] - Demand for refrigerants is being driven by new energy vehicles, air conditioning, and foreign trade [1] - The industry is experiencing a sustained upward trend in prosperity due to strong demand [1] Group 2 - There are dual opportunities in the market: rising prices for third-generation refrigerants and advancements in fourth-generation technology [1] - Focus on industry leaders with synchronized patent and capacity layouts is recommended [1] - Companies related to third-generation refrigerants are expected to benefit significantly [1]

Group 1 - The vaccine ETF (159643) has risen over 1.7%, driven by both policy and technological advancements in the pharmaceutical industry [1] - The vaccine industry is expected to see a recovery or continued growth in key vaccine products such as PCV13, diphtheria vaccine, and MCV4, supported by improved channel inventory [1] - The blood products sector is projected to experience steady growth in plasma collection volume in 2024, contributing to future growth [1] Group 2 - The IO multi-antibody, ADC, and GLP-1 fields are witnessing continuous validation of Chinese assets, enhancing international competitiveness and driving rapid industry development [1] - National policies are encouraging the development of innovative drugs, further supporting the growth of the pharmaceutical sector [1] - The vaccine ETF tracks the vaccine biotechnology index (980015), which reflects the overall performance of listed companies involved in vaccine research, production, and related biotech services [1]